• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类外周血T细胞上CTLA-4的表面及细胞内表达调控

Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells.

作者信息

Wang X B, Zheng C Y, Giscombe R, Lefvert A K

机构信息

Immunological Research Unit, Center for Molecular Medicine, Karolinska Institutet, SE-171 76 Stockholm, Sweden.

出版信息

Scand J Immunol. 2001 Nov;54(5):453-8. doi: 10.1046/j.1365-3083.2001.00985.x.

DOI:10.1046/j.1365-3083.2001.00985.x
PMID:11696196
Abstract

Cytotoxic T-lymphocyte-associated antigen (CTLA-4) is an important downregulator of T-cell activation. In order to analyze the expression and regulation of CTLA-4 on human peripheral T cells, CTLA-4 mRNA and protein expression were determined using analysis by reverse transcription-polymerase chain reaction (RT-PCR) and FACs, respectively. Intracellular CTLA-4 was constitutively expressed in unstimulated CD4+ and CD8+ T cells. Interleukin (IL)-2 induced a dose-dependent increase of both intracellular and surface expression of CTLA-4 (CD152). Most of the CD4+ and CD8+ cells expressing CTLA-4 also expressed CD25. Interferon (IFN)-gamma induced the upregulation of CTLA-4 expression via antigen-presenting cells (APC) activation. The CTLA-4delTM mRNA (550 bp) had a shorter half-life than the full length CTLA-4 mRNA and the expression was downregulated upon activation of the cells by treatment with IL-2. Given an inhibitory role of CTLA-4 and CD4+ CD25+ T cells in immune responses, the present findings suggest that IL-2-induced immunosuppression may result from its stimulatory effect of the CTLA-4 expression.

摘要

细胞毒性T淋巴细胞相关抗原(CTLA-4)是T细胞活化的重要负调节因子。为了分析CTLA-4在人外周血T细胞上的表达及调控情况,分别采用逆转录-聚合酶链反应(RT-PCR)分析和流式细胞术(FACs)测定CTLA-4 mRNA和蛋白表达。细胞内CTLA-4在未受刺激的CD4+和CD8+ T细胞中组成性表达。白细胞介素(IL)-2诱导CTLA-4(CD152)细胞内和表面表达呈剂量依赖性增加。大多数表达CTLA-4的CD4+和CD8+细胞也表达CD25。干扰素(IFN)-γ通过抗原呈递细胞(APC)活化诱导CTLA-4表达上调。CTLA-4delTM mRNA(550 bp)的半衰期比全长CTLA-4 mRNA短,在用IL-2处理激活细胞后其表达下调。鉴于CTLA-4和CD4+ CD25+ T细胞在免疫反应中的抑制作用,目前的研究结果表明,IL-2诱导的免疫抑制可能源于其对CTLA-4表达的刺激作用。

相似文献

1
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells.人类外周血T细胞上CTLA-4的表面及细胞内表达调控
Scand J Immunol. 2001 Nov;54(5):453-8. doi: 10.1046/j.1365-3083.2001.00985.x.
2
Expression of CTLA-4 by human monocytes.
Scand J Immunol. 2002 Jan;55(1):53-60. doi: 10.1046/j.0300-9475.2001.01019.x.
3
Cyclic adenosine 5'-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes.环磷酸腺苷(cAMP)和钙离子诱导静息CD4+ T淋巴细胞中CD152(CTLA-4)上调。
J Immunol. 2002 Dec 1;169(11):6231-5. doi: 10.4049/jimmunol.169.11.6231.
4
Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production.霍奇金病中血液淋巴细胞CTLA-4(CD152)诱导与增殖活性、白细胞介素2及γ干扰素产生的相关性
Br J Haematol. 2002 Jul;118(1):202-9. doi: 10.1046/j.1365-2141.2002.03572.x.
5
Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.HIV感染中CD4 + T细胞上CTLA-4(CD152)的表达增强。
Clin Exp Immunol. 1999 Mar;115(3):451-7. doi: 10.1046/j.1365-2249.1999.00806.x.
6
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).使用与表面相连的抗CTLA-4(CD152)单链抗体阻断T细胞活化。
J Immunol. 2000 May 1;164(9):4433-42. doi: 10.4049/jimmunol.164.9.4433.
7
Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.共刺激分子CD80和CD86及其受体CD28、CTLA-4在卵巢癌及其他类型腹膜癌患者恶性腹水中CD3⁺肿瘤浸润淋巴细胞(TIL)上的表达。
Clin Exp Immunol. 2000 Jan;119(1):19-27. doi: 10.1046/j.1365-2249.2000.01105.x.
8
A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells.通过可变剪接产生的可溶性CTLA-4形式由未受刺激的人T细胞表达。
Eur J Immunol. 1999 Nov;29(11):3596-602. doi: 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y.
9
Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction.人T细胞在激活早期获得CD80:CD80获得在T细胞与T细胞相互作用中的功能参与
J Immunol. 2002 Dec 1;169(11):6162-9. doi: 10.4049/jimmunol.169.11.6162.
10
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.细胞毒性T淋巴细胞相关抗原4(CTLA-4,即CD152)可通过两种不同机制抑制T细胞活化,具体取决于其细胞表面表达水平。
J Immunol. 2000 Aug 1;165(3):1352-6. doi: 10.4049/jimmunol.165.3.1352.

引用本文的文献

1
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy.实体瘤免疫治疗中新兴的新型免疫检查点抑制剂
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 11. doi: 10.1007/s00210-025-04131-w.
2
An IL-2 mutein increases regulatory T cell suppression of dendritic cells via IL-10 and CTLA-4 to promote T cell anergy.一种白细胞介素-2 突变体通过白细胞介素-10 和 CTLA-4 增加调节性 T 细胞对树突状细胞的抑制作用,从而促进 T 细胞无能。
Cell Rep. 2024 Nov 26;43(11):114938. doi: 10.1016/j.celrep.2024.114938. Epub 2024 Nov 2.
3
Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A.
双检查点适体免疫疗法:揭示针对CTLA-4和NKG2A的定制癌症治疗方法
Cancers (Basel). 2024 Mar 4;16(5):1041. doi: 10.3390/cancers16051041.
4
An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells.一种白细胞介素-2突变体可增强调节性T细胞对树突状细胞的白细胞介素-10和细胞毒性T淋巴细胞相关抗原4依赖性抑制作用。
bioRxiv. 2023 Dec 4:2023.12.01.569613. doi: 10.1101/2023.12.01.569613.
5
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors.组合阻断癌症免疫疗法:针对新兴免疫检查点受体。
Front Immunol. 2023 Oct 19;14:1264327. doi: 10.3389/fimmu.2023.1264327. eCollection 2023.
6
The C55A Single Nucleotide Polymorphism in Gene, a New Possible Biomarker in Thyroid Autoimmune Pathology Such as Hashimoto's Thyroiditis.基因中的C55A单核苷酸多态性,一种在甲状腺自身免疫性疾病如桥本甲状腺炎中可能的新生物标志物。
Diagnostics (Basel). 2023 Jul 28;13(15):2517. doi: 10.3390/diagnostics13152517.
7
Current understanding of CTLA-4: from mechanism to autoimmune diseases.CTLA-4 的现有认识:从机制到自身免疫性疾病。
Front Immunol. 2023 Jul 11;14:1198365. doi: 10.3389/fimmu.2023.1198365. eCollection 2023.
8
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.可溶性和细胞外囊泡相关 PD-L1、B7-H3 和 B7-H4 在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的预后作用。
Cells. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832.
9
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario.免疫检查点抑制剂内分泌和代谢毒性的管理:从临床研究到实际应用场景
Cancers (Basel). 2022 Dec 30;15(1):246. doi: 10.3390/cancers15010246.
10
Advances in the Lung Cancer Immunotherapy Approaches.肺癌免疫治疗方法的进展
Vaccines (Basel). 2022 Nov 19;10(11):1963. doi: 10.3390/vaccines10111963.